Hospital Allowed to Keep Report from Disclosure
In a decision that could influence discovery in federal medical-device products liability litigation, a Magistrate Judge in the U.S. District Court for the Northern District of New York has held that a state-law provision designed to encourage hospitals to maintain quality assurance and infection control programs without fear of litigation can be invoked to block disclosure of hospital records even where there is, at most, an indirect threat of a malpractice suit and where the…
The Hospital Defendant
It is said that 'doctors bury their mistakes.' At one time that may have been more true than in modern times, and when the original peer-review privileges case came out, it seemed as if it may have been more possible to bury culpable behavior in peer-review. That is not the case in 2007.
Failure to Warn
The author, Tim O'Brien, was appointed Lead Counsel by the U.S. District Court for the Southern District of New York in MDL No. 1789, <i>In re Fosomax Products Liability Litigation</i>. The opinions expressed herein are Mr. O'Brien's and represent some of the arguments the plaintiffs are or will be making in the litigation.
'If It Was Not Charted, It Was Not Done'
Documentation is an important part of medical care. Consultation notes, test results, physician orders and nursing observations all assist in ensuring continuity of care. In litigation, however, the significance of the written chart is often elevated from a tool for patient care to historical written account of past events. In this latter context, many in the medical community have advocated that if an event (an order, a consultation, a phone call, etc.) was not documented in the official patient record, it did not happen. Over time, this 'negative evidence' has been used to prove negligent omissions on the part of various care providers by showing that they failed to do something that they should have done, because if it had been done it would have been charted. The same 'lack of entry' evidence is also used to disprove (or create doubt) that an event testified to by a witness on the stand did not occur.
In the Marketplace
Highlights of the latest equipment leasing news from around the country.
Features
What Leasing Counsel Need to Know About Arbitration
Part One of this series analyzed the consideration that leasing counsel should give to discovery, locale selection, confidentiality, and expediting the arbitration process. This month's installment discusses issues relating to arbitrator-selection.
Features
Information Security Obligations
One of the most pressing issues faced by any business, but especially those in the financial services industry, is the privacy and security of financial and other nonpublic information. This is the first in a series of three articles addressing some of the key issues surrounding corporate responsibility with respect to the privacy of information and security breaches. Whether public or private, small company or large, if you or your client are in possession of the personal information described below, the following series of articles is essential reading.
Need Help?
- Prefer an IP authenticated environment? Request a transition or call 800-756-8993.
- Need other assistance? email Customer Service or call 1-877-256-2472.
MOST POPULAR STORIES
- Protecting Innovation in the Cyber World from Patent TrollsWith trillions of dollars to keep watch over, the last thing we need is the distraction of costly litigation brought on by patent assertion entities (PAEs or "patent trolls"), companies that don't make any products but instead seek royalties by asserting their patents against those who do make products.Read More ›
- Meet the Lawyer Working on Inclusion Rider LanguageAt the Oscars in March, Best Actress winner Frances McDormand made “inclusion rider” go viral. But Kalpana Kotagal, a partner at Cohen Milstein Sellers & Toll had already worked for months to write the language for such provisions. Kotagal was developing legal language for contract provisions that Hollywood's elite could use to require studios and other partners to employ diverse workers on set.Read More ›
- From the PTO to the FDA: What to Consider When Branding Clinical TrialsThe legal implications of branding generally arise initially for companies during the process of selecting a company name and any initial product or service names. For drug development companies, however, careful consideration should also be paid to the implications of branding a clinical trial.Read More ›
- Use of Deferred Prosecution Agreements In White Collar InvestigationsThis article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.Read More ›